CRISPR Therapeutics AG — Director's Dealing 2019

Sep 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2019-09-10

Reporting Person: Klein Lawrence Otto (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-09-10	Restricted Stock Units	$	A	10000	Acquired		Common Shares (10000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2: The restricted stock units shall vest in full on September 10, 2021, subject to continued employment with the company.